The Day after Tomorrow: How Should We Address Health System Organization to Treat Cancer Patients after the Peak of the COVID-19 Epidemic?
COVID-19 outbreak
Cancer
Health care systems
Oncology
Pandemic
Journal
Oncology
ISSN: 1423-0232
Titre abrégé: Oncology
Pays: Switzerland
ID NLM: 0135054
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
04
2020
accepted:
23
06
2020
pubmed:
20
7
2020
medline:
15
12
2020
entrez:
20
7
2020
Statut:
ppublish
Résumé
On March 11, 2020, the WHO director general declared COVID-19 a pandemic. This pandemic evolves in successive phases, i.e., phase 1 (the start phase), phase 2 ("the storm"), and phase 3 (the recession). To date, oncology and surgery groups have only given instructions for addressing phases 1 and 2. To prevent excess cancer mortality, health care systems (HCS) need to be restructured. Our aim is to detail the specificities of each epidemic phase and discuss several methods of organization to optimize cancer patient flow during the COVID-19 pandemic, particularly during phase 3. Hospitals must be reorganized in order to create a cancer hub that is free of infection, allowing for the safe treatment of patients. Hospital structures are different, but all allow for the creation of virus-free areas. Screening programs are critical and need to be applied to all people entering the virus-free zone, including health care workers. Some reorganization proposals are internal to a hospital, while others require interhospital collaboration. The heterogeneity and complexity of HCS will make interhospital management difficult. The ministry of health has an important role in managing the cancer crisis. Cancer management should be declared a priority. Oncological and surgical societies must coordinate their efforts to facilitate this prioritization. The anticipation of oncological management during phase 3 of the pandemic is necessary because it requires a complete readjustment of HCS. This adaptation should allow for the continuation of cancer care to prevent excess cancer mortality, as the virus will still be present for a currently undetermined period of time.
Identifiants
pubmed: 32683373
pii: 000509650
doi: 10.1159/000509650
pmc: PMC7445382
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
827-835Informations de copyright
© 2020 S. Karger AG, Basel.
Références
Int J Infect Dis. 2020 May;94:154-155
pubmed: 32179137
Ann Oncol. 2020 Jul;31(7):965-966
pubmed: 32278878
Eur Radiol. 2020 Aug;30(8):4417-4426
pubmed: 32279115
Open Forum Infect Dis. 2019 Oct 29;6(11):ofz462
pubmed: 32258201
F1000Res. 2014 Sep 12;3:221
pubmed: 25469231
Clin Psychol Psychother. 2020 May;27(3):384-395
pubmed: 32415733
J Visc Surg. 2020 Jun;157(3S1):S7-S12
pubmed: 32249098
Surgery. 2020 Aug;168(2):209-211
pubmed: 32425247
Gastroenterology. 2020 Sep;159(3):1164-1166.e3
pubmed: 32425228
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
J Hosp Infect. 2020 Jun;105(2):360-361
pubmed: 32278704
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
Travel Med Infect Dis. 2020 Mar - Apr;34:101624
pubmed: 32179125
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
Int J Environ Res Public Health. 2020 May 15;17(10):
pubmed: 32429172
JAMA. 2020 Apr 21;323(15):1439-1440
pubmed: 32163102
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Future Oncol. 2020 Apr;16(11):615-617
pubmed: 32266838
Auris Nasus Larynx. 2020 Aug;47(4):687-691
pubmed: 32425317
Australas Radiol. 2003 Jun;47(2):143-5
pubmed: 12780442
Colorectal Dis. 2020 Jun;22(6):642-643
pubmed: 32237263
Ann Oncol. 2020 Jul;31(7):840-843
pubmed: 32243893
Clin Transl Radiat Oncol. 2020 Mar 24;22:55-68
pubmed: 32274425
Ann Surg Oncol. 2020 Jun;27(6):1717-1720
pubmed: 32270420
Am Soc Clin Oncol Educ Book. 2018 May 23;38:540-545
pubmed: 30231354
Bull Cancer. 2020 Jul - Aug;107(7-8):730-737
pubmed: 32425210
Occup Med (Lond). 2020 Jul 17;70(5):364-369
pubmed: 32372077
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930